<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-1-1">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>			
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia: study design and inclusion criteria
			</div>


			<div class="content-container">
				

				<div class="content-left">
					
					<ul>
						<li><span>The pivotal study supporting eltrombopag use in SAA was an investigator-initiated, non-randomised study<sup>1</sup></li>
						<li><span>Primary objective: safety and efficacy of eltrombopag in refractory aplastic anaemia<sup>2</sup>
							<ul>
								<li><span>Secondary objectives included: analysis of the incidence and severity of bleeding episodes</span></li>
							</ul>
						</li>
						<li><span>Key inclusion criteria:<sup>1</sup></span>
							<ul>
								<li><span>Diagnosis of SAA</span></li>
								<li><span>Refractory thrombocytopenia persisting after ≥1 course of treatment with horse or rabbit antithymocyte globulin (h-/r-ATG) and ciclosporin</span>
									<ul>
										<li><span>The most recent course of ATG and ciclosporin should have been initiated more than 6 months before study enrolment</span></li>
									</ul>
								</li>
								<li><span>Platelet count ≤30,000 cells/mm<sup>3</sup></span></li>
							</ul>
						</li>
					</ul>

				</div>

				<div class="content-right">
					
					<div class="red-label">Final study design<sup>3</sup></div>

					<img src="media/images/slide_3-3-1-1/picture1.png" alt="">

				</div>

				

			</div>

		</div>

		<div class="information-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: study design and inclusion criteria</header>
				
			<ul>
				<li><span>This study was conducted by the National Institutes of Health (NIH) and the National Heart, Lung and Blood Institute (NHLBI)<sup>4</sup></span></li>
				<li><span>No financial support was provided to the NIH/NHLBI<sup>1</sup></span></li>
				<li><span>The study was originally designed to enrol and treat 25 patients<sup>3</sup></span>
					<ul>
						<li><span>Cohort 1 consisted of the initially enrolled patients (N=26)</span></li>
						<li><span>In April 2012, the protocol was amended to increase the total number from both study arms to a maximum of 45 patients</span></li>
						<li><span>Cohort 2 consisted of 18 additional patients enrolled</span></li>
						<li><span>Of the 44 patients enrolled, 43 were treated with eltrombopag (one patient gave consent but was not treated)</span></li>
						<li><span>Eltrombopag 50 mg once daily was selected as the starting dose for this study (and doses were escalated up to maximum of 150 mg) because this regimen has been demonstrated to be safe and effective in patients with chronic immune thrombocytopenia or hepatitis C<sup>3,5,6</sup></span></li>
						<li><span>A starting dose of 25 mg once daily was selected for East Asian patients because of ethnopharmacological differences in exposure<sup>3</sup></span></li>
					</ul>
				</li>
			</ul>

		</div>

		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Olnes M <i>et al. N Engl J Med</i> 2012;367:11</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>GlaxoSmithKline. Data on File. Study protocol #09-H-0154. 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>ClinicalTrials.gov. NCT00922883. http://clinicaltrials.gov/show/NCT00922883. Updated January 2014 (accessed February 2014)</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Cheng G <i>et al. Lancet</i> 2011;377:393;</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Afdhal NH <i>et al. Gastroenterology</i> 2014;146:442</span></li>
			</ol>

		</div>

	</div>
</div>